By Shepard Ambellas | Intellihub.com
Experimental drug “brincidovir” fast-tracked by FDA
NORTH CAROLINA — Chimerix, a biopharmaceutical firm, has been approved by the FDA under fast-tracking to administer “brincidofovir”, a new and experimental antiviral drug aimed at fighting the deadly Ebola virus.
The Hill reports:
The drug has also been tested by the Centers for Disease Control and Prevention and the National Institutes of Health, though it is not expected to win approval for wide public use until late 2016.
“We are hopeful that brincidofovir may offer a potential treatment for Ebola Virus Disease during this outbreak,” the company’s president and CEO, M. Michelle Berrey, said in a release.